Findings

What do systematic reviews say?

4 questions · 5 findings · 1 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 5 · 100%Moderate 0 · 0%High 0 · 0%

Mepolizumab 750 mg vs placebo

Exacerbations · patients with chronic obstructive pulmonary disease

Mepolizumab 750 mg showed no clear difference in number of participants experiencing an exacerbation within 6 months compared with placebo (low certainty).

2 findings from 1 review

Anti‐IL‐5 therapies for chronic obstructive pulmonary disease 2020 · Cochrane Headline outcomes only
Odds ratio 0.43 [0.06, 2.97]
1 study · 18 participants
Low
Anti‐IL‐5 therapies for chronic obstructive pulmonary disease 2020 · Cochrane Headline outcomes only
Odds ratio 9 [0.75, 108.31]
1 study · 18 participants
Low

Mepolizumab 750 mg vs placebo

Serious adverse events · patients with chronic obstructive pulmonary disease

Mepolizumab 750 mg showed no clear difference in serious adverse events compared with placebo (low certainty).

1 finding from 1 review

Anti‐IL‐5 therapies for chronic obstructive pulmonary disease 2020 · Cochrane Headline outcomes only
Odds ratio 3 [0.22, 40.93]
1 study · 18 participants
Low

Mepolizumab 750 mg vs placebo

Health‐related quality of life (HRQL) · patients with chronic obstructive pulmonary disease

1 finding from 1 review

Anti‐IL‐5 therapies for chronic obstructive pulmonary disease 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 18 participants
Low

Mepolizumab 750 mg vs placebo

Lung function (FEV₁) · patients with chronic obstructive pulmonary disease

1 finding from 1 review

Anti‐IL‐5 therapies for chronic obstructive pulmonary disease 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 18 participants
Low